AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Telix Pharmaceuticals Limited (ASX:TLX) operates in the healthcare sector and is engaged in commercialisation and development of molecularly targeted radiation (MTR) products for the treatment of cancer. The company is based out of North Melbourne, Australia.
Telixâs Clinical Pipeline (Image source: Companyâs report)
TLX has recently inked a deal with the Emory Winship Cancer Institute for a Clinical Trial using Advanced Imaging of Prostate Cancer for Radiotherapy. Ashesh Jani (Winship Radiation Oncologist) and David Schuster (Emory Radiologist and Nuclear Medicine Physician) will be leading the trial. The trial involves numerous ingenious purposes such as the first use of PSMA PET in Georgia. With the said study, the Emory University continues its tradition of innovation and development.
Insights into the deal
A grant amounting to US$3.4 million by the National Institutes of Health has been offered to the researchers at the Winship Cancer Institute, Emory University in Atlanta, USA. The underlying purpose is to compare Axumin® against Ga-PSMA in high-risk prostate cancer patients that will be receiving radiation therapy following prostatectomy. Telix will provide the PSMA PET imaging for the study and act as a Technology Partner and Collaborator for the grant. The study will be conducted on a population of 140 patients.
As per a prior comparative experience between PSMA imaging and Axumin®, PSMA imaging came out to be superior in terms of detection. Axumin® was developed by Emory University and is approved for metastatic prostate cancer currently in the US.
The study is aimed at identifying any advanced prostate imaging techniques to guide radiotherapy. The research will help evaluate prostate imagingâs potential to impact the implementation of radiotherapy techniques.
Also, Telix is selected as a part of the study on account of the ongoing collaborative clinical study of Ga-PSMA imagingâs future implications. The company has provided easy to use products that have made nuclear pharmacy validation straightforward. The collaboration with Emory Winship Cancer Institute is expected to be a great step forward in the domain.
Steps towards the development of illumetâ¢
Recently, Telix has also made progress with the development of illumetâ¢. It has put forward a pre-New Drug Application meeting request to the US Food and Drug Administration. The purpose is to obtain a marketing authorisation for the illumet⢠prostate cancer imaging product in the United States.
The meeting with the FDA is expected to take place in the month of July, and the company has prepared a comprehensive pre-NDA package for the same. For the product, Telix also has other distribution partners. It recently executed a distribution agreement with United Pharmacy Partners Inc. The company has also entered into another agreement with PharmaLogic, located in the Northeast and Western United States. The deals mentioned above helped Telix to expand its distribution network and strengthen its presence in the US market. The deals have also provided extended partnering options for the company.
Currently, the stock of the company is trading at a price of $1.055, with a market capitalisation of $216.18 million as on 31st May 2019.
Disclaimer
This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.
